Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Crucially, pharma companies are not and will not pursue indications for GLP-1 drugs for addiction because they avoid studying unstable populations due to reputational risk and market-size uncertainty
This data-driven approach ensures you source a product that is both effective and commercially viable
He WJ, Shi MM, Yang P, Huang T, Zhao Y, Wu AB, Dong WB, Li HP, Zhang JB, Liao YC (2020) A quinone-dependent dehydrogenase and two NADPH-dependent aldo/keto reductases detoxify deoxynivalenol in wheat via epimerization in a Devosia strain
And today as we speak, our customer base total as on end of April holds almost two-thirds of the Indian market share by value of the generic market We are the first and the only CDMO partner for the first three generic Semaglutide approvals in all the highly regulated markets, US and Canada. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma | Q4 FY26 Gland Pharma is running the same play with cartridges capacity expanded from 40 million to 140 million units a year, eight GLP-1 contracts signed, six or seven more in the pipeline
MariTide: This investigational drug from Amgen might only need to be injected once a month, which would be a massive win for convenience
The company currently has three medications in clinical trials
US$ 23.09
US$ 28.47
US$ 22.50
US$ 25.88
US$ 25.10
